Aclaris Therapeutics (ACRS) Long-Term Investments (2014 - 2026)

Aclaris Therapeutics' Long-Term Investments history runs 10 years deep, the most recent figure standing at $85.4 million for Q1 2026.

• In Q1 2026, Long-Term Investments changed 0.19% year-over-year to $85.4 million; the TTM figure through Mar 2026 stood at $85.4 million (changed 0.19% YoY), while the FY2025 annual figure was $60.6 million, down 32.88% from the prior year.
• Long-Term Investments was $85.4 million for Q1 2026 at Aclaris Therapeutics, up from $60.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $91.0 million in Q2 2023 to a low of $7.2 million in Q2 2022.
• Historically, Long-Term Investments has averaged $56.6 million across 5 years, with a median of $61.7 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments tumbled 79.07% in 2022, then jumped 1160.1% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $12.2 million in 2022, then soared by 412.75% to $62.8 million in 2023, then soared by 43.86% to $90.3 million in 2024, then slumped by 32.88% to $60.6 million in 2025, then soared by 40.85% to $85.4 million in 2026.
• The last three Long-Term Investments figures came in at $85.4 million (Q1 2026), $60.6 million (Q4 2025), and $71.3 million (Q3 2025), per Business Quant data.